Study guide
12.1 Injection and Vaccine Administration Technique
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
12.1 Injection and Vaccine Administration Technique
Key Takeaways Explain This Topic AI
The deltoid is the standard intramuscular site for adults and children aged 1 year and older, using a 22 to 25 gauge needle of 25 mm inserted at 90 degrees.
Aspiration before intramuscular injection is not recommended, because there are no large vessels at the recommended sites and aspiration increases pain.
Anaphylaxis after immunization is treated with intramuscular epinephrine 0.01 mg/kg of the 1 mg/mL concentration into the anterolateral thigh, to a maximum of 0.5 mg.
Vaccines are stored between +2 and +8 degrees Celsius; a freezing excursion destroys adjuvanted vaccines and the affected doses must be quarantined, not used.
A 15-minute post-immunization observation period is the standard, extended to 30 minutes for a history of anaphylaxis or significant vaccine anxiety.
Last updated: August 2026
12.1 Injection and Vaccine Administration Technique
Exam Focus: "Medication administration" is a distinct subcategory of the Pharmacy Practice blueprint, and the syllabus specifies "skills required for safe and effective administration of vaccines and medications by injection in selected populations." Items test site, needle, dose, and the immediate management of a reaction.
Authority and Preparation
Injection administration by pharmacists is authorised under provincial legislation, and every province requires documented injection training and current cardiopulmonary resuscitation certification before a pharmacist may inject. The permitted list of injectable products, the minimum patient age, and the requirement for a prescription vary between provinces, so verify local authority rather than assuming a national rule.
Before any injection:
Confirm identity, indication, and informed consent, and screen for contraindications and precautions.
Review allergy history, current anticoagulation, immunosuppression, pregnancy, and prior reactions.
Confirm that epinephrine and an emergency response plan are immediately available.
Check the product name, concentration, expiry, appearance, and, where relevant, the diluent.
Perform hand hygiene. Gloves are not routinely required for immunization unless the administrator has open skin lesions or contact with blood is anticipated.
Route, Site, and Needle Selection
Route Angle Needle gauge and length Typical volume
Intramuscular (IM) 90 degrees 22 to 25 gauge; 25 mm standard for adults, 16 mm for infants in the vastus lateralis Up to 1 mL in the deltoid
- Subcutaneous (SC) 45 to 90 degrees 25 to 27 gauge; 10 to 16 mm Up to 1 mL
- Intradermal 5 to 15 degrees, bevel up 26 to 27 gauge; 10 mm 0.1 mL, raising a bleb
Site selection:
Deltoid — the standard intramuscular site for anyone aged 1 year and older. Locate it by finding the acromion process and injecting into the thickest part of the muscle, roughly two to three finger widths below it, above the level of the axilla. Injecting too high risks shoulder injury related to vaccine administration, a preventable and well-recognised complication.
Vastus lateralis — the anterolateral thigh, the intramuscular site for infants under 1 year and the site of choice for emergency epinephrine at any age.
Ventrogluteal — used for larger volumes and viscous depot preparations.
Subcutaneous sites — the fatty tissue of the posterolateral upper arm, the abdomen avoiding a 5 cm radius around the umbilicus, and the anterior thigh.
Do not aspirate before an intramuscular injection. There are no large blood vessels at the recommended sites, aspiration prolongs the procedure and increases pain, and current Canadian immunization guidance advises against it.
When more than one vaccine is given at the same visit, use separate sites at least 2.5 cm apart, or separate limbs, and record which product went where.
Technique and Comfort
Position the patient seated with the limb relaxed; a tense muscle makes injection more painful. Clean the site with alcohol only if visibly soiled, and allow it to dry fully — injecting through wet alcohol stings and can inactivate live vaccines.
Insert smoothly and briskly, inject at a steady rate, withdraw, and apply gentle pressure without massage. Pain-reduction techniques with real evidence include the rapid injection without aspiration described above, giving the most painful product last, breastfeeding or sucrose for infants, topical anaesthetic where time permits, distraction, and having the patient sit rather than lie down for adults.
Sharps safety: activate the safety device immediately, never recap, and dispose directly into an approved puncture-resistant sharps container at the point of use. A needlestick injury requires immediate washing, reporting, and post-exposure risk assessment for hepatitis B, hepatitis C, and human immunodeficiency virus.
Managing Immediate Adverse Events
Event Presentation Management
Vasovagal syncope Pallor, sweating, light-headedness, brief loss of consciousness; occurs within minutes and the patient is warm with a normal or slow pulse Lie the patient flat with legs elevated; recovery is prompt
Anaphylaxis Urticaria, angioedema, wheeze, stridor, hypotension; the patient is unwell and deteriorating Intramuscular epinephrine immediately; call emergency services
Local reaction Soreness, redness, swelling Cool compress, analgesia; reassure
Distinguishing syncope from anaphylaxis is a favourite examination point: syncope is common, immediate, and resolves when the patient lies down; anaphylaxis involves skin, respiratory, or cardiovascular compromise and worsens without treatment. When genuinely uncertain, treat as anaphylaxis, because epinephrine given to a person who has fainted causes little harm and withholding it in anaphylaxis is life-threatening.
Epinephrine dosing: 0.01 mg/kg of the 1 mg/mL (1:1000) solution intramuscularly into the anterolateral thigh, to a maximum of 0.5 mg in adults and 0.3 mg in children, repeatable every 5 to 15 minutes. Confirm the concentration on the ampoule before drawing up; the 0.1 mg/mL (1:10,000) presentation is for intravenous use in cardiac arrest and is not interchangeable.
Observe every patient for 15 minutes after immunization, extended to 30 minutes for those with a history of anaphylaxis, significant needle anxiety, or a prior post-immunization reaction.
Cold Chain
Vaccines and many biologics are stored at +2 to +8 degrees Celsius .
Use a purpose-built vaccine refrigerator with a continuously recording thermometer, not a domestic bar fridge or a food refrigerator.
Record minimum and maximum temperatures at least twice daily and document the readings.
Keep vaccines in the middle of the fridge away from walls, vents, and the door; use water bottles to stabilise temperature.
On a temperature excursion , quarantine the affected stock, label it "do not use", and contact the public health authority or manufacturer for a viability assessment. Do not destroy or administer it on your own judgement.
Freezing is not reversible. Adjuvanted and aluminium-containing vaccines are destroyed by freezing even if they later thaw and appear normal.
Transport in a validated cooler with a temperature monitor and a barrier that prevents direct contact with ice packs.